Last reviewed · How we verify
MDV3100 — Competitive Intelligence Brief
marketed
Androgen receptor inhibitor
Androgen receptor, Glucocorticoid receptor, Prostate-specific antigen
Oncology
Live · refreshed every 30 min
Target snapshot
MDV3100 (mdv3100) — Pfizer Inc..
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MDV3100 TARGET | mdv3100 | Pfizer Inc. | marketed | Androgen receptor inhibitor | Androgen receptor, Glucocorticoid receptor, Prostate-specific antigen | |
| Talazoparib with enzalutamide | talazoparib-with-enzalutamide | Pfizer | marketed | PARP inhibitor and androgen receptor inhibitor | PARP enzymes and androgen receptor | Not yet launched |
| Winlevi | CLASCOTERONE | Sun Pharma | marketed | Androgen Receptor Inhibitor [EPC] | Androgen receptor | 2020-01-01 |
| Xtandi | enzalutamide | Astellas Pharma | marketed | Androgen Receptor Inhibitor [EPC] | Androgen receptor | 2012-01-01 |
| Xtandi | xtandi | Astellas Pharma | marketed | Androgen receptor inhibitor | Androgen receptor | 2012-01-01 |
| Nilandron | NILUTAMIDE | Advanz | marketed | Androgen Receptor Inhibitor [EPC] | Androgen receptor | 1996-01-01 |
| BICALUTAMIDE | BICALUTAMIDE | marketed | Androgen Receptor Inhibitor [EPC] | 1995-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Androgen receptor inhibitor class)
- Aragon Pharmaceuticals, Inc. · 1 drug in this class
- Arvinas Androgen Receptor, Inc. · 1 drug in this class
- Astellas Pharma · 1 drug in this class
- AstraZeneca · 1 drug in this class
- City of Hope Medical Center · 1 drug in this class
- Pfizer Inc. · 1 drug in this class
- Tata Memorial Centre · 1 drug in this class
- Triple Hair Inc · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- MDV3100 CI watch — RSS
- MDV3100 CI watch — Atom
- MDV3100 CI watch — JSON
- MDV3100 alone — RSS
- Whole Androgen receptor inhibitor class — RSS
Cite this brief
Drug Landscape (2026). MDV3100 — Competitive Intelligence Brief. https://druglandscape.com/ci/mdv3100. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab